SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending amid speculation of a potential buyout or partnership, possibly involving TikTok or OpenAI, driving significant volume. The community is buzzing about a possible short squeeze, new AI AR smart glasses and the potential impact of any deal on Snap's ad business. Chatter suggests the stock may be undervalued, with some eyeing a gap fill and others anticipating a major move this week.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

IREN is trending due to significant GPU purchases to expand its AI cloud capabilities, detailed in a recent Seeking Alpha article. Community discussions revolve around the company's growth potential and future data center capacity, with some expressing bullish sentiment and anticipating further upward movement. The stock's performance is also being compared to others in the AI infrastructure and Bitcoin mining sectors.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP.X is trending amidst a broader crypto dip, sparking debates about market manipulation and future price predictions. While some community members are expressing frustration and calling for lower prices to buy more, others remain optimistic, citing upcoming ETFs and Ripple's involvement in talks between the U.S. and U.K. regarding crypto cooperation as potential catalysts.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as community members discuss the company's groundbreaking on its first Aurora powerhouse in Idaho and a Wedbush price target hike, fueling debate about the company's valuation and future potential in the clean energy sector. While some see a promising long-term play with policy tailwinds, others express concerns about the pre-revenue status, potential dilution, and insider selling, creating a battleground between bulls and bears.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending due to the appointment of Mike Alfred to its board, sparking excitement among investors about the company's growth strategy in digital assets and AI. Community members are actively discussing Alfred's potential impact and the broader implications for Bakkt's position in the fintech landscape. This news arrives as the company navigates its evolving role in the crypto sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending as community members weigh in on its potential, debating whether recent price movements are a short squeeze or driven by genuine accumulation. Discussions also involve the company's technology and potential acquisitions, with some cautioning against the stock's valuation. The stock's price action is attracting attention as it trades alongside sector peers.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

MBX Biosciences Inc.

MBX Biosciences is trending following the announcement of positive topline results from its Phase 2 trial of Canvuparatide, with community members discussing the potential for significant gains and highlighting the responder rates. Some caution that it is only phase 2 data while others point to a possible upcoming offering due to limited cash. The company is focused on developing therapies for endocrine and metabolic disorders.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending as investors discuss its recent registered direct offering priced at a premium, signaling strong institutional interest and confidence in the company's execution. Community members are actively debating the implications of this offering, particularly in relation to Bitmine's Ethereum holdings and potential for future growth within the crypto space. Some traders are taking advantage of short-term dips, while others express a long-term bullish outlook on the stock.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

$PFE is trending due to the announced acquisition of Metsera in a deal to expand Pfizer's presence in the obesity drug market, sparking community discussion around the deal's value and potential impact. Some investors believe Pfizer overpaid, while others anticipate further acquisitions in the obesity and related sectors, with speculation around potential targets like $VKTX and $ALT. The acquisition reflects a broader interest in obesity treatments, with communities weighing the competitive landscape and potential for new drugs.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the crypto market experiences volatility, leading to community discussions around potential market manipulation and accumulation strategies. Some traders are closely watching technical indicators and key support levels, while others are speculating on the impact of upcoming events like staking rewards for ETH ETFs. The community is weighing the potential for both short-term pullbacks and a longer-term breakout towards new highs.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer Inc. (PFE) on Monday said that it will acquire biopharmaceutical company Metsera (MTSR) for $47.50 per share in cash at closing.The upfront purchase price of $47.50 per share represents a premium of 43% from Metsera’s closing share price on Friday. The deal represents a total enterprise value of approximately $4.9 billion for Metsera.Metsera shareholders will also receive a non-transferable contingent value right (CVR) entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones. The transaction is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250922965053/en/Pfizer-to-Acquire-Metsera-and-its-Next-Generation-Obesity-Portfolio">expected</a> to close in the fourth quarter of 2025, subject to the satisfaction of customary closing conditions.Shares of Metsera soared 59% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MTSR">MTSR</a> jumped from ‘bullish’ to ‘extremely bullish' territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.New York City-based Metsera is a clinical-stage biopharmaceutical company developing medicines for obesity and cardiometabolic diseases.<a href="https://stocktwits.com/symbol/PFE">Pfizer</a> said on Monday that the proposed acquisition will add four highly differentiated clinical-stage programs to Pfizer’s pipeline, including MET-097i, a weekly and monthly injectable GLP-1 receptor agonist, and MET-233i, a monthly amylin analog candidate, in addition to two other oral GLP-1 receptor agonists expected to begin clinical trials soon. GLP-1 receptor agonists are a class of medications that mimic the effects of the body's natural hormone glucagon-like peptide-1 (GLP-1) to treat type 2 diabetes and obesity. Amylin analogs, likewise, can lead to weight loss.“Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area,” said Pfizer CEO Albert Bourla. Pfizer scrapped its own obesity drug candidate, Danuglipron, earlier this year.The Financial Times had on Sunday <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-metsera-7b-buyout-obesity-drug-race-lilly-novo/chDQXfYR3c9">reported</a> that the two companies could announce a deal as early as Monday.While Pfizer’s stock has declined 9% so far in 2025, Metsera’s stock has risen 25.7% over the same period.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/micron-stock-gets-a-price-target-hike-from-stifel/chDQNFpR3cz">Micron Stock Gets A Price Target Hike From Stifel Ahead Of Q4 Earnings – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Metsera Stock Surges 59% Pre-Market After Pfizer Confirms Acquisition – Here Are The Details

The upfront purchase price of $47.50 per share implies a premium of 43% from Metsera’s closing share price on Friday.

Equity

The upfront purchase price of $47.50 per share implies a premium of 43% from Metsera’s closing share price on Friday.


Pfizer is reportedly preparing to buy weight-loss biotech Metsera in a deal that could be worth as much as $7.3 billion.The New York-based drugmaker would apparently pay $47.50 a share upfront and another $22.50 tied to milestones, a sharp premium to Metsera’s recent price of $33.32. An announcement could come as early as Monday, barring last-minute delays, according to a Financial Times&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/aee4a71c-7ad6-4cde-852f-720a97542fac">report</a>,&nbsp;which cited two people familiar with the matter.The move comes after Pfizer scrapped its own obesity drug candidate, danuglipron, earlier this year. Metsera, which is listed in one of 2025’s biggest biotech IPOs, has drawn interest across the sector with MET-097i, a GLP-1 therapy that produced 11.3% weight loss over 12 weeks in a mid-stage trial.&nbsp;The company is also developing a monthly version of the shot, an amylin-based treatment aimed at avoiding muscle loss, and an oral pill. Pfizer shares, now worth about half their 2021 pandemic peak, closed Friday at $24, valuing the company at $136 billion.&nbsp;CEO Albert Bourla has been under pressure to reignite growth, with Pfizer’s last major deal being the $43 billion purchase of cancer drugmaker Seagen in 2023. A Metsera acquisition would put it in direct competition with Eli Lilly and Novo Nordisk, whose blockbuster GLP-1 drugs Zepbound and Wegovy are expanding into pill form.On Stocktwits, retail sentiment for both Pfizer and Metsera was ‘bullish’, with message volume ‘normal’ for Pfizer and ‘high’ for Metsera.One user&nbsp;labeled the reported deal value&nbsp;a “lousy premium” to Metsera’s recent trading levels and argued the company’s management may be selling too cheaply. The user added that Pfizer may have avoided a bigger gamble on Viking Therapeutics ahead of late-stage trials.<stembedurl>https://stocktwits.com/biolover/message/629465706</stembedurl>Another bullish user said that the acquisition could ultimately be seen as an $80-per-share buyout opportunity.<stembedurl>https://stocktwits.com/vu_jade/message/629466433</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> has declined 4.6% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MTSR">Metsera’s stock</a> has risen 25.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Stock Draws Focus On Report Of $7.3B Deal Plan For Metsera Buyout As Obesity Drug Race With Lilly, Novo Heats Up

Pfizer is pushing into the booming weight-loss market after its own drug setback, as rivals Eli Lilly and Novo Nordisk lead the field.

PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?

AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.

Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?

CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.

MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response

Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.

U.S. stocks experienced a modest pullback from their record highs as a strong August retail sales report tempered hopes of a bigger cut by the Federal Reserve at the September rate-setting meeting.Most experts and market watchers expect the central bank, led by Chair Jerome Powell, to cut rates by 25 basis points to 4-4.25%, with a section of them bracing for a “Sell the news” move.&nbsp; Former JPMorgan strategist Marko Kolanovic warned of a potential spike in volatility. In a post on X, he&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/markoinny/status/1968126762883383583">said</a>, “Systematic investors are maxed out. Potentially an explosive situation (like this April) when volatility increases.”Ahead of the crucial Fed meeting, the following stocks saw increased trading volume in Tuesday’s extended trading session.Nvidia Corp. (NVDA)After-hours move: +0.15%Trading volume: 7.6 millionNvidia’s stock fell for a second straight session on Tuesday, dragged by another negative China headline. The stock ended the session down 1.61% after a Reuters report, citing two people, said the company’s new artificial intelligence (AI) inference chip, the RTX6000D, has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-s-china-focused-ai-chip-reportedly-struggles-to-win-big-buyers/chwyfEWRdyp">poor uptake&nbsp;</a>in the country.The&nbsp;<a href="https://stocktwits.com/symbol/NVDA">Nvidia stock</a> continued to elicit ‘bearish’ sentiment (43/100) from among the retail users of Stocktwits, and the message volume also stayed at ‘low’ levels.The stock has gained 30% year-to-date (YTD).Pfizer, Inc. (PFE)After-hours move: +0.17%Trading volume: 7.49 million<a href="https://stocktwits.com/symbol/PFE">Pfizer shares,</a> which are down 5% YTD, came on investors’ radar amid the oversold levels of the stock. Health and Human Services Secretary Robert Kennedy Jr.’s stance on vaccines and the resultant divisions within the department have also shifted the focus on vaccine developers, including Pfizer.Retail sentiment toward the stock stayed ‘bullish’ (61/100) and the message volume remained at ‘high’ levels.New Fortress Energy LLC (NFE)After-hours move: +35.49%Trading volume: 27.92 million<a href="https://stocktwits.com/symbol/NFE">New Fortress Energy stock</a> surged higher in the after-hours&nbsp;following a 45%&nbsp;jump in regular trading. The after-hours surge came after the company struck a long-term liquefied natural gas (LNG) <a href="https://stocktwits.com/news-articles/markets/equity/new-fortress-energy-stock-surges-on-4-b-puerto-rico-deal-lng-supply-deal/chDGfqMRdCJ">supply contract </a>with Puerto Rico.&nbsp;"Matching our LNG production with long-term offtake has always been our goal. This locks in sustainable long-term margins for NFE and provides a foundation of financial stability for our company," said Chris Guinta, CFO of New Fortress Energy.The New York-based integrated gas-to-power company has lost about 87% of its valuation this year due to investor worries concerning its debt, even as project delays weigh down. The strength seen in the stock is due to hopes that the company would reach a deal to restructure its debt.Retail sentiment toward the stock has improved to ‘extremely bullish’ (93/100) by late Tuesday, from ‘bullish’ a day ago, and the message volume rose to ‘extremely high’ levels.Tesla, Inc. (TSLA)After-hours move: +0.29%Trading volume: 4.33 millionTesla stock outperformed the broader market on Tuesday as it climbed 2.77% despite the S&amp;P 500’s modest pullback. The stock is steadily moving toward its highest level this year, thanks to a few catalysts, including CEO Elon Musk buying $1 billion worth of shares, the billionaire renewing his commitment toward the electric-vehicle business, optimism over the robotaxi opportunity, and expectations of delivery outperformance in the third quarter.The stock is still trading way off its all-time high of $488.54.On Stocktwits, retail traders stayed ‘extremely bullish’ (91/100) toward the&nbsp;<a href="https://stocktwits.com/symbol/TSLA">Tesla stock</a>, and the message volume continued to be ‘extremely high.’Tesla’s stock is up 4.40% for the year.Alphabet, Inc. (GOOGL) (GOOG)After-hours move: +0.04%Trading volume: 4.16 millionAlphabet, which is the newest $3 trillion club member, saw its shares retreat modestly on Tuesday.&nbsp;<a href="https://stocktwits.com/symbol/GOOG">Alphabet’s Class C stock</a> is up 32.45% this year. Sentiment toward the stock, however, remained ‘bearish’ (42/100), and the message volume dropped to ‘normal’ levels.Alphabet announced a $5 billion AI investment, while it faces a lawsuit from sell-side advertising company Magnite (MGNI), with the latter seeking financial damages and remedies following the U.S. District Court for the Eastern District of Virginia’s April ruling which found Google “willfully engaged in a series of anticompetitive acts to acquire and maintain monopoly power" in the ad exchange and ad server markets.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-stock-edges-up-after-hours-another-ai-heavyweight-jumps-aboard/chDGB18RdC5">Paramount Skydance Stock Edges Up After-Hours: Another AI Heavyweight Jumps Aboard While WBD Merger Talk Swirls</a>

Traders work on the floor of the New York Stock Exchange during afternoon trading on August 01, 2025 in New York City. (Photo by Michael M. Santiago/Getty Images)

Nvidia, Pfizer, New Fortress Energy, Tesla, Alphabet: What Sparked Heavy After-Hours Trading In These 5 Stocks?

 Nvidia stayed on investors’ radar amid the stock price volatility, while a contract win buoyed sentiment toward the beaten-down stock of LNG company New Fortress Energy.

MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer

Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.

Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?

GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.

CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?

CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know  

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

https://files.quartr.com/streams/2025-09-22/4fe3ba3f-37a0-49c7-8354-3d09f0bb8fd3/1/live_transcript.jsonl?ref=U3RvY2t0d2l0cw==

M&A Announcement

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PFE News

PFE Pfizer Inc